(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 June 2022 (16.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/126133 A1

(51) International Patent Classification:
A61K 31/5025 (2006.01) *A61P 1/00* (2006.01)
A61K 31/5377 (2006.01)

(21) International Application Number:
PCT/US2021/072858

(22) International Filing Date:
10 December 2021 (10.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/123,894 10 December 2020 (10.12.2020) US
63/166,621 26 March 2021 (26.03.2021) US

(71) Applicant: **SUMITOMO PHARMA ONCOLOGY,INC.** [US/US]; 640 Memorial Drive, Cambridge, MA 02139 (US).


(72) Inventors: **FRANZ, Bettina**; c/o Sumitomo Dainippon Pharma Oncology, Inc., 640 Memorial Drive, Cambridge, MA 02139 (US). **SIDDIQUI-JAIN, Adam**; c/o Sumitomo Dainippon Pharma Oncology, Inc., 640 Memorial Drive, Cambridge, MA 02139 (US). **WARNER, Steven, L.**; c/o Sumitomo Dainippon Pharma Oncology, Inc., 640 Memorial Drive, Cambridge, MA 02139 (US). **BASIREDDY, Siva, Reddy**; c/o Aragen Life Sciences Private Limited, Plot 28A, IDA Nacharam, Hyderabad, Telangana 500076 (IN). **PADAKANTI, Srinivas**; c/o Aragen Life Sciences Private Limited, Plot 28A, IDA Nacharam, Hyderabad, Telangana 500076 (IN). **KUMAR, Naresh**; c/o Aragen Life Sciences Private Limited, Plot 28A, IDA Nacharam, Hyderabad, Telangana 500076 (IN).

(74) Agent: **SIMMONS, Rebecca, L.** et al.; Hamilton, Brook, Smith & Reynolds, P.C., 530 Virginia Rd, P.O. Box 9133, Concord, MA 01742-9133 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ALK-5 INHIBITORS AND USES THEREOF



(I)

(57) Abstract: Provided herein are compounds (*e.g.*, compounds of Formulae (I), (II), (III) and (IV), or of Table 1 or Table 4), and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and kits comprising the same. The compounds provided herein are activin receptor-like kinase (*e.g.*, ALK-5) inhibitors and are, therefore, useful, for example, for treating and/or preventing diseases (*e.g*, proliferative diseases, such as cancer) in a subject, inhibiting tumor growth in a subject, or inhibiting the activity of an activin receptor-like kinase (*e.g.*, ALK-5) *in vitro or in vivo*. Also provided herein are methods and synthetic intermediates useful in the preparation of compounds described herein.

WO 2022/126133 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*